Passa al contenuto
Merck
  • Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate.

Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate.

Clinical pharmacology and therapeutics (2013-06-13)
J Trottier, M Perreault, I Rudkowska, C Levy, A Dallaire-Theroux, M Verreault, P Caron, B Staels, M-C Vohl, R J Straka, O Barbier
ABSTRACT

Glucuronidation, catalyzed by uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, detoxifies cholestatic bile acids (BAs). We aimed to (i) characterize the circulating BA-glucuronide (BA-G) pool composition in humans, (ii) determine how sex and UGT polymorphisms influence this composition, and (iii) analyze the effects of the lipid-lowering drug fenofibrate on the circulating BA-G profile in 300 volunteers and 5 cholestatic patients. Eleven BA-Gs were determined in pre- and postfenofibrate samples. Men exhibited higher BA-G concentrations, and various genotype/BA-G associations were discovered in relevant UGT genes. The chenodeoxycholic acid-3G (CDCA-3G) concentration was associated with the UGT2B7 802C>T polymorphism. Glucuronidation assays confirmed the predominant role of UGT2B7 and UGT1A4 in CDCA-3G formation. Fenofibrate exposure increased the serum levels of five BA-G species, including CDCA-3G, and upregulated expression of UGT1A4, but not UGT2B7, in hepatic cells. This study demonstrated that fenofibrate stimulates BA glucuronidation in humans and thus reduces BA toxicity in the liver.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Fenofibrate, ≥99%, powder
Supelco
Fenofibrate, Pharmaceutical Secondary Standard; Certified Reference Material
Fenofibrate, European Pharmacopoeia (EP) Reference Standard